Fac­ing a pay­er back­lash over stick­er shock, Bio­gen fields pos­i­tive da­ta on Spin­raza for chil­dren 2-12

Fight­ing an up­hill bat­tle to get pay­ers to cov­er its $750,000 first-year price tag on Spin­raza (nusin­ersen), Bio­gen is post­ing an­oth­er round of stel­lar da­ta to back its use among old­er chil­dren with rare cas­es of spinal mus­cu­lar at­ro­phy.

Re­searchers test­ed the drug in 126 SMA pa­tients who were be­tween the ages of 2 and 12 and gen­er­al­ly suf­fered from Type 2 or Type 3 forms of the neu­ro­mus­cu­lar dis­ease. As we’ve al­ready seen with in­fants un­der 6 months suf­fer­ing ear­ly-on­set dis­ease, there was a clear re­sponse, with a 3.9 point im­prove­ment at month 15 in the Ham­mer­smith Func­tion­al Mo­tor Scale Ex­pand­ed (HFMSE) score, com­pared to a 1.0 point drop in pa­tients in the place­bo arm.

Al San­drock, Bio­gen

“In CHER­ISH, most chil­dren with lat­er-on­set SMA treat­ed with Spin­raza saw im­prove­ments in mo­tor func­tion and sta­bi­liza­tion or slow­ing of dis­ease pro­gres­sion,” said Dr. Richard Finkel, chief of neu­rol­o­gy, Nemours Chil­dren’s Hos­pi­tal, Or­lan­do, Flori­da. “As a physi­cian who has spent 37 years treat­ing chil­dren with SMA, it’s in­cred­i­bly en­cour­ag­ing to see some pa­tients on Spin­raza achieve mile­stones such as crawl­ing and stand­ing with as­sis­tance with­in the clin­i­cal tri­al. These kinds of clin­i­cal­ly mean­ing­ful im­prove­ments are un­prece­dent­ed and give new hope to in­di­vid­u­als with SMA and their fam­i­lies.”

But it’s pay­ers that Bio­gen most wants to im­press now.

“We’re hope­ful that when [health plans] see this da­ta, they will up­date their poli­cies” to cov­er the drug for old­er chil­dren, Bio­gen Chief Med­ical Of­fi­cer Al San­drock told the home­town news­pa­per Boston Globe.

Bio­gen, part­nered with Io­n­is, stunned some an­a­lysts with its price, which drops to half that $750,000 in the sec­ond year, or $1.5 mil­lion for the first three years of treat­ment. Leerink’s Ge­of­frey Porges not­ed re­cent­ly that the price could turn Spin­raza in­to the “So­val­di of rare dis­ease drugs,” com­par­ing it to the Gilead hep C cure that sparked an out­cry over the $1,000-per-pill cost.

Bio­gen bad­ly needs to make a suc­cess of Spin­raza. Its flag­ship drug Tec­fidera has been flag­ging as new com­peti­tors hit the MS mar­ket, and it has a thin pipeline of CNS drugs that most an­a­lysts would like to see fat­tened through new deals. Along those lines Bio­gen lined up a $300 mil­lion up­front deal a few days ago to grab an an­ti-tau drug from Bris­tol-My­ers Squibb. And more deals may be on the way.

“We’re mov­ing, and we’re back in terms of aug­ment­ing the pipeline,” re­search and de­vel­op­ment head Michael Ehlers told Bloomberg on Fri­day.

Pres­i­dent Trump, mean­while, has been cas­ti­gat­ing the in­dus­try for as­tro­nom­i­cal drug prices, though rare dis­ease drugs have gen­er­al­ly avoid­ed the spot­light among all the price con­tro­ver­sies that have erupt­ed in the last cou­ple of years.

Regeneron CEO Leonard Schleifer speaks at a meeting with President Donald Trump, members of the Coronavirus Task Force, and pharmaceutical executives in the Cabinet Room of the White House (AP Photo/Andrew Harnik)

OWS shifts spot­light to drugs to fight Covid-19, hand­ing Re­gen­eron $450M to be­gin large scale man­u­fac­tur­ing in the US

The US government is on a spending spree. And after committing billions to vaccines defense operations are now doling out more of the big bucks through Operation Warp Speed to back a rapid flip of a drug into the market to stop Covid-19 from ravaging patients — possibly inside of 2 months.

The beneficiary this morning is Regeneron, the big biotech engaged in a frenzied race to develop an antibody cocktail called REGN-COV2 that just started a late-stage program to prove its worth in fighting the virus. BARDA and the Department of Defense are awarding Regeneron a $450 million contract to cover bulk delivery of the cocktail starting as early as late summer, with money added for fill/finish and storage activities.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,700+ biopharma pros reading Endpoints daily — and it's free.

Donald and Melania Trump watch the smoke of fireworks from the South Lawn of the White House on July 4, 2020 (via Getty)

Which drug de­vel­op­ers of­fer Trump a quick, game-chang­ing ‘so­lu­tion’ as the pan­dem­ic roars back? Eli Lil­ly and Ab­Cellera look to break out of the pack

We are unleashing our nation’s scientific brilliance and will likely have a therapeutic and/or vaccine solution long before the end of the year.

— Donald Trump, July 4

Next week administration officials plan to promote a new study they say shows promising results on therapeutics, the officials said. They wouldn’t describe the study in any further detail because, they said, its disclosure would be “market-moving.”

— NBC News, July 3

Something’s cooking. And it’s not just July 4 leftovers involving stale buns and uneaten hot dogs.

Over the long weekend observers picked up signs that the focus in the Trump administration may swiftly shift from the bright spotlight on vaccines being promised this fall, around the time of the election, to include drugs that could possibly keep patients out of the hospital and take the political sting out of the soaring Covid-19 numbers causing embarrassment in states that swiftly reopened — as Trump cheered along.

So far, Gilead has been the chief beneficiary of the drive on drugs, swiftly offering enough early data to get remdesivir an emergency authorization and into the hands of the US government. But their drug, while helpful in cutting stays, is known for a limited, modest effect. And that won’t tamp down on the hurricane of criticism that’s been tearing at the White House, and buffeting the president’s most stalwart core defenders as the economy suffers.

We’ve had positive early-stage vaccine data, most recently from Pfizer and BioNTech, playing catchup on an mRNA race led by Moderna — where every little sign of potential trouble is magnified into a lethal threat, just as every advance excites a frenzy of support. But that race still has months to play out, with more Phase I data due ahead of the mid-stage numbers looming ahead. A vaccine may not be available in large enough quantities until well into 2021, which is still wildly ambitious.

So what about a drug solution?

Trump’s initial support for a panacea focused on hydroxychloroquine. But that fizzled in the face of data underscoring its ineffectiveness — killing trials that aren’t likely to be restarted because of a recent population-based study offering some support. And there are a number of existing drugs being repurposed to see how they help hospitalized patients.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

In­vestors give ail­ing Unum a lease on life and a whole new suite of ex­per­i­men­tal can­cer drugs

Investors, it seems, are willing to give Unum Therapeutics one last shot — or at least one last shot to a company of that name.

The ailing cancer biotech, beset by a series of clinical holds and multiple failed lead programs, announced today that they’ve acquired Kiq LLC and that investors are putting in $104 million to advance Kiq’s pipeline of kinase inhibitors. Unum shareholders will now own only 16.2% of the company and CEO Chuck Wilson indicated that the cell therapies the biotech has worked on since its founding may be on their way out, saying Unum will “explore strategic options” for those products.

RA Cap­i­tal dou­bles down on Sid­dhartha Mukher­jee's vi­sion for a new cell en­gi­neer­ing ap­proach, lead­ing Vor's $110M Se­ries B

Vor Biopharma is muscling up.

CEO Robert Ang, who was reluctant to divulge the headcount when discussing his move from Neon Therapeutics to Vor last August, readily offered that the team has grown from 6 to 50 in less than a year. The biotech is moving to a larger office on Cambridge Parkway Drive in weeks, giving it more space to complete the IND-enabling work and manufacturing scale-up — conducted by a CDMO partner — in preparation for clinical trials planned for the first half of 2021.

Shoshanna Shendelman, Applied Therapeutics CEO (Applied Therapeutics)

A lit­tle biotech slaps back at a 'crim­i­nal' short at­tack, vow­ing to pur­sue a pros­e­cu­tion of their case

As short attacks go, Biotech Research Partners’ assault on Applied Therapeutics’ “cherry picked” data and a variety of so-called red flags didn’t cause a whole lot of damage. Ahead of the July 4 holiday, its shares $APLT were dinged and showed signs of quick recovery.

But that didn’t stop an incendiary response, as the biotech swung into action bright and early Monday morning.

Applied Therapeutics accused the authors of the short report of manipulating graphs and figures, misrepresenting data and included factual misrepresentations — all of which added up, in their view, to fraud.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,700+ biopharma pros reading Endpoints daily — and it's free.

Covid-19 roundup: Left out no longer, No­vavax se­cures largest Warp Speed deal yet: $1.6B

It looks like Novavax won’t be left out of Operation Warp Speed after all.

A month after the Gaithersburg, MD biotech saw its shares tumble when it was left off the first reported list of finalists for the White House’s Covid-19 vaccine accelerator, HHS and the Department of Defense have announced a $1.6 billion deal to scale up their Covid-19 candidate. It is the largest deal HHS has announced yet, eclipsing the $1.2 billion deal the administration reached with AstraZeneca in May.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,700+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: Im­munomedics spells out PFS ben­e­fit of Trodelvy in mTNBC, hunt­ing a full OK just weeks af­ter ac­cel­er­at­ed ap­proval

By the time the FDA finally granted an accelerated OK for Immunomedics’ Trodelvy, we already got a very strong hint that their confirmatory Phase III study in metastatic triple-negative breast cancer was a success.

That’s because the independent data safety monitoring committee recommended that the trial be stopped early. But just what pointed them to the conclusion was still unclear.

“We do not know the totality of their decision other than it’s pretty evident that the primary endpoint was met; otherwise they could not request to halt the study,” Behzad Aghazadeh, the executive chairman, told Endpoints News at the time.

Cel­lec­tis slammed af­ter pa­tient dies and FDA slaps a hold on their tri­al for an off-the-shelf CAR-T for mul­ti­ple myelo­ma

Cellectis was slammed after the market close on Monday as the biotech reported that the FDA demanded it hit the brakes on their MELANI-01 trial for their off-the-shelf cell therapy UCARTCS1A after one of the patients in the study died of treatment-related cardiac arrest.

The multiple myeloma patient had previously been treated unsuccessfully with various therapies, noted the biotech, and had been given dose level two (DL2) of their allogeneic CAR-T.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,700+ biopharma pros reading Endpoints daily — and it's free.

Jean-Paul Clozel, Idorsia CEO (Patrick Straub/Keystone via AP Images)

Sec­ond PhI­II study for Idor­si­a's sleep drug re­turns pos­i­tive re­sults, but al­so rais­es new ques­tions

Following a successful Phase III study in April showcasing the safety and potential of its new sleep drug, Idorsia posted some mixed news in the second Phase III study, but that won’t stop a planned filing aimed at regulatory approval.

The drug, a dual orexin receptor antagonist (DORA) called daridorexant, was found to significantly improve sleep maintenance and subjective total sleep time in 25 mg doses, replicating results from the first Phase III study. However, improvements in sleep onset and daytime functioning narrowly missed statistical significance, despite numerical consistency with the April study.